González Enguita C, Roncalés Badal A, Gil Sanz M J, Martínez Bengoechea J, Tello Royloa C, Rioja Sanz L A
Servicio de Urología, Hospital Miguel Servet, Zaragoza.
Actas Urol Esp. 1990 Sep-Oct;14(5):335-8.
Management of renal cells carcinoma still remains a therapeutic challenge. Nephrectomy is the primary therapy when the disease has a definite location. In advanced or disseminated cases, the various traditional procedures, including radiotherapy, chemotherapy or hormonal regimes, have obtained poor responses. Survival shows a direct relationship with the biological aggressiveness of the tumour and histological factors. Results recorded in the literature using specific immunotherapeutic agents are encouraging although the real value of this regimes has not yet been established in large series of prospective studies. The Oncology Unit of our Urology Service has obtained optimal follow-up in a group of patients included in a combined protocol of interferon alpha-2a and vinblastine as cytotoxic agent.
肾细胞癌的治疗仍然是一项治疗挑战。当疾病有明确部位时，肾切除术是主要治疗方法。在晚期或播散性病例中，包括放疗、化疗或激素疗法在内的各种传统治疗方法效果不佳。生存率与肿瘤的生物学侵袭性和组织学因素直接相关。尽管在大量前瞻性研究中尚未确定这种治疗方案的真正价值，但文献中使用特定免疫治疗药物的记录结果令人鼓舞。我们泌尿外科的肿瘤科对一组纳入干扰素α-2a和长春碱作为细胞毒性药物联合方案的患者进行了最佳随访。
